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Susanne Heck4, Richard Ellis4, Pawan Dhami4, Ulrich D. Kadolsky4, Michelle Kleeman4, Yogesh Kamra4, David J. Fear1, Susan John1,
Wayel Jassem5, Richard W. Groves6, Jeremy D. Sanderson7, Michael D. Robson1, David P. D’Cruz1, Mats Bemark3,8*, and Jo Spencer1*
B cells emerge from the bone marrow as transitional (TS) B cells that differentiate through T1, T2, and T3 stages to become
naive B cells. We have identified a bifurcation of human B cell maturation from the T1 stage forming IgMhi and IgMlo
developmental trajectories. IgMhi T2 cells have higher expression of α4β7 integrin and lower expression of IL-4 receptor
(IL4R) compared with the IgMlo branch and are selectively recruited into gut-associated lymphoid tissue. IgMhi T2 cells also
share transcriptomic features with marginal zone B cells (MZBs). Lineage progression from T1 cells to MZBs via an IgMhi
trajectory is identified by pseudotime analysis of scRNA-sequencing data. Reduced frequency of IgMhi gut-homing T2 cells is
observed in severe SLE and is associated with reduction of MZBs and their putative IgMhi precursors. The collapse of the gut-
associated MZB maturational axis in severe SLE affirms its existence in health.
Introduction
Transitional (TS) B cells are the immature B cells in human
blood from which all mature B cells develop. Following emi-
gration from the bone marrow, TS B cells mature through
transitional stage 1 (T1), T2, and T3 phases, when autoreactive
cells are depleted (Palanichamy et al., 2009; Suryani et al., 2010;
Yurasov et al., 2005).
In mice, a B cell lineage split that is dependent on B cell re-
ceptor engagement and the serine/threonine kinase Taok3 is
initiated at the T1 phase (Hammad et al., 2017). This directs
B cells toward marginal zone B (MZB) cell fate, requiring sub-
sequent Notch2 cleavage by a disintegrin and metalloproteinase-
containing protein 10 (ADAM10).
MZB lineage progression in humans is not clearly understood
or, indeed, universally accepted. A MZB precursor (MZP) pop-
ulation has been proposed that undergoes terminal differentia-
tion to MZB following Notch 2 ligation and can be discriminated
from naive B cells by expression of high levels of IgM (IgMhi),
CD24, and the glycosylation-dependent epitope CD45RBMEM55
(referred to here as CD45RB). An additional CD45RBhi IgMhi
population that lacks the ABCB1 cotransporter has previously
been referred to as T39, although the relationships among this
subset, MZBs, and MZPs is unclear (Bemark et al., 2013;
Descatoire et al., 2014; Koethe et al., 2011; Zhao et al., 2018).
In humans, MZBs develop over the first 2 yr of life and are
important for immunity against encapsulated bacteria (Weller
et al., 2004). They undergo a phase of clonal expansion and
receptor diversification in the germinal centers (GCs) of gut-
associated lymphoid tissue (GALT; Zhao et al., 2018; Weill and
Reynaud, 2020). The shared expression of MAdCAM1 between
the splenic marginal zone reticular cells and GALT high endo-
thelial venules creates the potential to recruit B cells to both sites
mediated by α4β7 integrin binding (Kraal et al., 1995; Vossenkämper
et al., 2013). We have described the expression of β7 integrin
(used here and previously as a surrogate for α4β7) by T2 B cells
in humans and observed their selective recruitment into GALT,
where they become activated (Vossenkämper et al., 2013).
Therefore, exposure to the GALT microenvironment could be
associated with multiple stages of MZB cell development from
as early as the T2 stage.
The systemic autoimmune disease systemic lupus erythe-
matosus (SLE), in particular the severe variant lupus nephritis
(LN), has markedly distorted profiles of B cell subsets in blood.
The TS B cell pool is expanded, as is the B cell subset lacking both
CD27 and IgD (so-called double-negative [DN] B cells; Landolt-
Marticorena et al., 2011; Wei et al., 2007). Disproportionate ex-
pansion of a population of DN cells lacking expression of CD21
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and CXCR5 and with up-regulated CD11c (DN2 cells) is a par-
ticular feature of LN (Jenks et al., 2018). DN2 cells may be de-
rived from activated naive B cells (aNAV), driven by TLR7
engagement, resulting in the generation of self-reactive antibody–
producing plasma cells (Jenks et al., 2018; Tipton et al., 2015).
Interestingly, a recent study of a cohort of newly diagnosed pa-
tients with SLE demonstrated that MZBs may be reduced in fre-
quency (Zhu et al., 2018). Since we have previously shown that TS
B cells in SLE may have significantly reduced expression of β7
integrin, we were interested to know if this may be associated
with defective MZB development and the increase in aNAV and
DN2 cells.
Here, we identify bifurcation in human B cell development
from the T2 stage. Cells in one branch are IgMhi, express β7
integrin, and are gut homing. Cells in the alternative IgMlo
branch have high expression of IL-4R, lower expression of β7
integrin, and do not tend to enter the gut. Transcriptomically,
IgMhi T2 cells share features with MZBs. B cell development
progresses from T1 to MZBs via an IgMhi trajectory by pseudo-
time analysis. IgMhi T2 cells are stably IgMhi in culture and have
a greater tendency to make IL-10 than IgMlo cells. A markedly
reduced frequency of IgMhiβ7hi T2 cells was seen in patients
with severe SLE, and this was associated with stark reduction in
cell populations associated with MZB development. Our data
link reduced access of IgMhi T2 cells to GALT with defects in all
stages of MZB differentiation and enables the assimilation of
these elements of human MZB differentiation into a model of
human B cell development.
Results
Segregation of B cell phenotypes from T2 through naive
B cell subsets
In mice, B cells commit to MZB differentiation soon after bone
marrow emigration at the T1 stage. To seek evidence of this in
humans, a deep phenotypic analysis of peripheral blood mono-
nuclear cells (PBMCs) from healthy control donors (HCDs) was
undertaken by mass cytometry (Fig. S1, A–C). Spanning tree
progression of density normalized events (SPADE) on viSNE
identified B cell subsets including TS B cells represented by
CD27−IgD+CD24+++/++CD38+++/++ nodes that included CD10+ T1
and T2 cells as well as CD10− T3 cells (Fig. 1 A; Qiu et al., 2011;
Zhao et al., 2018). T3 cells can only be definitively distinguished
from naive cells by their failure to extrude dyes such as rho-
damine 123 (R123) due to lack of the ABCB1 cotransporter
(Wirths and Lanzavecchia, 2005; Fig. S1 D). Since mass cytom-
etry cannot be used to detect dye extrusion, the boundary be-
tween T3 and naive B cells was estimated to generate the TS
SPADE bubble.
To perform a deep phenotypic analysis of TS B cells, events
within the TS B cell bubble identified in Fig. 1, A and B, were
exported and reclustered by SPADE on viSNE using all expressed
panel markers and then grouped according to gradients of loss of
CD10, CD38, and CD24 and gain of CD21 corresponding to T1, T2,
and T3 stages of differentiation (Bemark, 2015; Fig. 1 B). The
SPADE trees branched, forming two chains of nodes that each
extended through the T2 and T3 SPADE bubbles with no lateral
connections between the branches. Branches differed most no-
tably in their expression of IgM (Fig. 1 C). IgMhi T2 B cells also
had lower expression of CCR7 but higher expression of β7 in-
tegrin than IgMlo T2 cells by mass cytometry (Fig. 1 D) and
quantitative PCR (qPCR; Fig. 1 E). The amount of IGHD or IGHM
transcripts did not differ between IgMhi and IgMlo T2 cells,
suggesting that posttranslational mechanisms account for vari-
able surface immunoglobulin expression as previously reported
(Bell and Goodnow, 1994; Enders et al., 2014; Fig. 1 E). Further-
more, increased IgM surface expression was not associated with
a reduction in surface IgD expression as IgMhi T2 B cells had high
expression of both immunoglobulin isotypes (Fig. 1 F). In addi-
tion, IgMhi T3 cells had higher median expression of CD24 and
CD45RB than IgMlo T3 cells (Fig. 1, B and G).
In the SPADE analysis of all CD19+ B cells, nodes representing
IgMhi TS B cells were continuous with IgMhi naive B cells, and
IgMlo TS B cells were continuous with IgMlo naive cells (Fig. 1, A
and H). Principal-component analysis (PCA) using all markers
expressed by cells in nodes identified in Fig. 1 H grouped IgMhi
TS B cells closest to IgMhi naive B cells and most distant to IgMlo
TS B cells (Fig. 1 I). The major contributors to PCA1 and PCA2 in
addition to IgM and IgD were mediators of cell traffic (Fig. 1 J).
Human B cells therefore segregate phenotypically as T1 cells
enter into the T2 stage, forming two branches that differ in their
expression of IgM and in markers of migratory potential. IgMhi
T2 cells resemble IgMhi naive cells more closely than they re-
semble IgMlo T2 cells with which they share markers of
differentiation.
GALT is enriched in IgMhi T2 cells
Human TS B cells can home to GALT, where they become acti-
vated (Vossenkämper et al., 2013). To determine whether the
high expression of β7 integrin on IgMhi TS B cells is associated
with selective recruitment into GALT, mass cytometry was used
to compare B cells isolated from paired blood and gut biopsy
specimens from individuals undergoing surveillance colonos-
copies (n = 7; Fig. S1, A–C). TS B cells are a small subset, and due
to low mononuclear cell yields from GALT biopsies, data from
individual samples were concatenated. SPADE on viSNE was
then used to identify CD10+ T1 and T2 B cells within the total
CD19+ population (Figs. 2 A and S1 E). The undirected clustering
algorithm FlowSOM (Van Gassen et al., 2015) was then used to
group T1 and T2 B cells. This identified six metaclusters and the
identity of each cluster was deduced from the relative expres-
sion of CD21, CD24, CD38, and IgM (Fig. 2, B and C). This dem-
onstrated that IgMhi T2 cells are enriched in GALT,whereas both
T1 and IgMlo T2 cells are depleted compared with PBMCs (Fig. 2,
D and E). GALT T2 cells were predominantly represented by
metacluster 4, while the majority of T2 cells in PBMCs were
represented bymetacluster 3 (Fig. 2, B and E). Metacluster 4 had
higher expression of IgM, CD5, CD24, and CD38 but lower ex-
pression of CD21, CD22, CD23, and CCR7 than metacluster 3 (Fig.
S1 F). Within GALT, IgMhi T2 cells had higher expression of the
activation markers CD69 and CD80 compared with PBMCs
(Fig. 2 E).
Having observed that IgMhi T2 cells are enriched in GALT, we
sought confirmation of selective recruitment by asking whether
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Figure 1. Segregation of B cell phenotypes from T2 through naive B cell subsets. (A) SPADE on viSNE plots generated using the following markers that
were used to identify B cell subsets: CD10, CD24, CD27, CD38, CD45RB, IgD, IgM, IgA, and IgG. The plots are from a female HCD and are representative of 10
HCDs. Nodes represent a cluster of phenotypically similar cells, the size of a node is proportional to the number of cells represented by it, and the color
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this population is depleted from blood that has passed through
the gut. Blood from the gut passes to the liver via the hepatic
portal vein that also receives a contribution from the splenic
vein. We therefore isolated lymphocytes from liver perfusion
samples that would be depleted of cells that entered the gut.
Using the gating strategy displayed in Fig. S1 D, liver perfusate
samples were observed to be enriched in T1 cells as reported
previously (Vossenkämper et al., 2013; Fig. 2 F), and CD24hiIgMhi
T2 and IgMhi naive cells were depleted compared with PBMCs
from HCDs (Fig. 2, G–I), consistent with their selective recruit-
ment from blood into GALT.
Transcriptomic analysis of IgMhi and IgMlo TS B cells
demonstrates different upstream regulators of phenotype
Having demonstrated contrasting surface phenotypes and mi-
gratory capacity of IgMhi and IgMlo TS B cells, we next sought to
identify transcriptomic features differing between them and to
gain insight into inducers and regulators of these subsets by
single-cell RNA sequencing. IgMhi and IgMlo TS B cells from five
HCDs were sorted by FACS and pooled, and gene expression
libraries were prepared using a 10x Genomics single-cell 59 gene
expression workflow (Fig. S2, A–D). In total, 14,499 genes were
identified in 4,268 cells after quality filtering. The nonlinear
dimension reduction algorithm UMAP (uniform manifold ap-
proximation and projection; Becht et al., 2018) was run on dif-
ferentially expressed genes and demonstrated discreet
clustering of IgMhi and IgMlo TS B cells (Fig. 3 A). Selected genes
from the top 60 differentially expressed genes are illustrated in
Fig. 3, B and C. Transcripts encoding CD1C and MZB1 that are
expressed by MZB cells were among the most abundantly ex-
pressed genes in IgMhi TS B cells. The lupus risk allele and reg-
ulator of TLR9 responses PLD4was the most highly differentially
expressed gene in IgMhi TS B cells (Gavin et al., 2018). Undirected
clustering of pooled IgMhi or IgMlo TS B cells generated clusters
that contained predominantly IgMhi or IgMlo TS B cells (Fig. 3, D
and E) that shared enrichment of the genes expressed by these
cell subsets (Fig. 3, B and F). High expression of IL4R by IgMlo TS
and IgMlo naive B cells was confirmed by flow cytometry (Fig. S2,
E and F). Importantly, KLF2,which drives murine follicular B cell
development, was up-regulated in IgMlo TS B cells (Hart et al.,
2011). CCR7 was up-regulated in IgMlo TS B cells supporting the
higher surface expression that was evident in themass cytometry
analysis. Higher abundance of transcripts encoding L-selectin by
IgMlo TS B cells was also confirmed by qPCR using sorted pop-
ulations (Fig. S2, G and H).
Ingenuity pathway analysis demonstrated enrichment of
retinoic acid receptor and LPS-induced genes in IgMhi TS B cells
(Fig. S2, I and J). IgMlo TS B cells were enriched in genes induced
by IFN-γ, IL-1, and IL-2 (Fig. S2 K). IgMhi TS B cells used less VH1
and more VH3 than IgMlo TS B cells, consistent with published
profiles of the MZB repertoire (Bagnara et al., 2015; Fig. S2 L).
IgMhi and IgMlo TS B cells therefore have distinct tran-
scriptomes. IgMlo cells are selectively enriched in genes encod-
ing peripheral circulation and inhibition of MZB cell fate,
whereas IgMhi cells have gene expression signatures and IGHV
gene family usage linking them to MZB cells.
The abundance of CD1C transcripts in IgMhi TS B cells was of
particular interest, because CD1c is characteristically highly
expressed by humanMZBs (Weller et al., 2004). Consistent with
the transcriptomic profile, CD1c surface expression was higher
on IgMhi than IgMlo TS B cells (Fig. 3, G and H). As previously
reported, CD1c expression was high on MZBs (Fig. 3 I) as well
as on MZP and CD45RBhi T3 cells (previously referred to as
T39) that have been linked to MZB development (Bemark
et al., 2013; Descatoire et al., 2014; Koethe et al., 2011; Zhao
et al., 2018). MZP and CD45RBhi T3 cells were defined by the
phenotype CD27−IgD+CD10−CD45RBhi with expression of the
ABCB1 cotransporter or not, respectively (Fig. S1 D and Fig. 3,
J–L). Cells that express the ABCB1 cotransporter extrude R123
and are therefore identified as R123lo cells in this analysis.
Both subsets share high expression of IgM and CD24 (Fig. S2,
M and N).
Lineage progression from IgMhi TS B cells through toMZB cells
The shared surface properties of IgMhi TS with IgMhi naive
B cells (Fig. 1 I), the enrichment of transcripts considered
characteristic of MZBs in IgMhi TS B cells (Fig. 3, B and F), and
shared high expression of CD1c by IgMhi TS with MZBs and
other B cell subsets associated with MZB development (Fig. 3, H
and L) all support the existence of an IgMhi MZB differentiation
pathway that begins during TS B cell development. We inves-
tigated this further by performing pseudotime trajectory
analysis of single-cell RNA-sequencing data from HCD B cells
from blood.
CD19+ B cells were sorted from PBMCs of three HCD (Fig. S3
A) and surface labeled with Total-Seq-C antibodies before cap-
ture on the 10x Genomics chromium controller (Fig. S3 B). Gene
expression and antibody detection tag (ADT) libraries were then
prepared according to the manufacturer’s instructions and se-
quenced on an Illumina HiSeq High Output platform (Fig. S3 C).
indicates the median expression of a given marker. Nodes representing B cell subsets were grouped into bubbles as indicated by the schema to the left.
(B) SPADE on viSNE plots of TS B cells exported from the TS SPADE bubble in A and generated by rerunning viSNE using all expressed B cell markers. The
SPADE plots depicted are from a female HCD and are representative of 10 HCDs. TS B cell populations were defined as T1 (CD10+CD24+++CD38+++CD21lo), T2
(CD10+CD24++CD38++CD21hi), and T3 (CD10−CD24+CD38+CD21hi). (C) SPADE trees demonstrating that T2 and T3 TS B cells have prominent IgMhi and IgMlo
subpopulations. (D) SPADE trees demonstrating that IgMhi T2 B cells have higher expression of β7 integrin and lower expression of CCR7 than IgMlo T2 B cells.
(E) qPCR quantification of CCR7, ITGB7 (β7 integrin), IGHM, and IGHD transcripts from sorted subsets expressed as 2−ΔCT values relative to 18S endogenous
control (paired t test). *, P < 0.05; **, P < 0.01. (F) SPADE demonstrating that IgMhi T2 B cells also have high surface IgD expression. (G) SPADE aligns IgMhi T2
cells with IgMhi T3 cells with relatively high expression of CD45RB. (H) A SPADE on viSNE plot from A demonstrating the identification of IgMhi TS and naive
B cell populations. (I) A PCA plot generated using all expressed markers on IgMhi and IgMlo subsets identified in H. Data points represent individual HCD (n = 10)
and are surrounded by 95% confidence ellipses with a larger central mean data marker. (J) Variable contribution bar graphs demonstrate that homing receptors
are major contributors to PCA1 and PCA2 in I. The dashed red reference line represents the value where the contribution was uniform.
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Figure 2. GALT is enriched in IgMhi T2 cells. (A) SPADE on viSNE plots depicting the expression of B cell lineage markers used to identify T1 and T2 cells as
CD27−IgD+CD10+ in a concatenated (n = 7) GALT sample. GC, IgD−CD10+; M only, IgM-only memory (CD27+IgD−IgM+); PB, plasmablast (IgD−CD38hi; see also Fig.
S1 E). (B) A minimal spanning tree generated by FlowSOM run on exported events (n = 4,520 from each tissue) from the TS bubble in A using CD10, CD24,
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Data from single HCDs were initially analyzed individually.
UMAP plots were used to visualize clusters and identify the
B cell subsets they corresponded to by overlaying signal from
lineage-defining transcripts and CITE-seq (cellular indexing of
transcriptomes and epitopes by sequencing) antibodies (Fig. S3,
D and E). TS B cells were identified as CD27−IgD+ clusters with
high surface expression of CD38. Of the remaining CD27−IgD+
clusters that represented naive cells, those with the top 30% of
median IgM ADT signal were designated IgMhi (Fig. S3, D–G).
Note that because identification ofMZPs and CD45RBhi T3would
require reagents that are incompatible with this method (Fig. 3 J),
theywill be included in the IgMhi naive cell groups in this analysis.
CD27+IgD+ clusters that were enriched in CD1C transcripts were
designated as MZBs. CD27+IgD−IgM+ clusters were designated
“IgM-only” cells, and CD27+IgD−IgM− clusters enriched in HOPX
and COCH transcripts were designated as class-switched memory
B cells (Descatoire et al., 2014; Fig. S3, D–G).
Three-dimensional (3D) UMAP plots were then used to better
visualize the spatial relationship between these B cell subsets
(Fig. 4, A–D; and Fig. S3, H and I). This demonstrated clear
separation of CD27+ and CD27− “islands” of cells (Fig. 4, A–D; Fig.
S3, H and I; and Videos 1, 2, and 3). In all three HCDs, two distinct
cellular “bridges” linked the CD27− and CD27+ islands in the plot
(Fig. 4, A and B; Fig. S3, H and I; and Videos 1, 2, and 3). In each
HCD, an IgMhi bridge that was enriched in cells with CD1C
transcripts linked the CD27− island toMZBs (Fig. 4, A–D; and Fig.
S3, H and I). In contrast, IgM-only cells were connected to the
CD27− island by naive cells with lower expression of IgM.
Having visualized the juxtaposition of IgMhi naive cells with
MZB in UMAP clusters we next used the Slingshot tool for
pseudotime trajectory analysis. Data from the three HCD were
normalized and integrated. UMAP plots were used to identify
clusters representing CD27−CD38hiCD24hi TS B cell and
CD27+IgD+IgM+ MZB subsets by overlay of CD27, IgM, IgD and
CD38 ADT signal (Fig. 4, E and F). The TS B cell cluster was
selected as the starting point for analysis of pseudotime tran-
sitions in Slingshot. Importantly, end points were not specified.
Slingshot identified an IgMhi pseudotime trajectory from TS
B cells that passed through the MZB cluster via IgMhi naive
B cells (Street et al., 2018; Fig. 4 G and Video 4). Among the 100
most differentially expressed genes along this trajectory were
PLD4, CD1C, SOX4, andMZB1, which were previously identified as
differentially expressed between IgMhi and IgMlo TS B cells
(Fig. 3, B and F; and Fig. 4, H and I). Analysis of gene expression
by cells along the trajectory demonstrated progressive down-
regulation of IGLL5 and VPREB1 markers of B cell immaturity
(Fig. 4 H). Up-regulated in the terminal stages of the trajectory
were genes encoding proteins implicated in cell adhesion, in-
cluding ITGB2, PCDH9, and activation, including DAPP1 (Fig. 4, H
and I). The final cluster in the pseudotime trajectory was en-
riched in the IFN-regulated gene MX1 and the transcription
factor ZEB2 (Fig. 4, H and I). IFN-induced genes as well as DAPP1
and FCRL5 are highly expressed by DN2 cells, although the re-
lationship of this subset with MZB is not known (Jenks et al.,
2018). Pseudotime analysis of HCD PBMCs therefore identified
an IgMhi developmental trajectory from TS B cells to MZBs.
IgMhi and IgMlo TS B cells differ functionally and in their
potential to differentiate
We next determined if IgMhi and IgMlo TS B cells that have
different cell surface and transcriptomic characteristics main-
tain their relative levels of IgM expression in vitro following
stimulation and if they differ functionally. Initially, proliferation
in response to anti-IgM in the presence of CD40L was measured.
IgMhi TS B cells proliferated more than IgMlo cells in response to
anti-IgM (Fig. 5, A and B). Next, we investigated the response of
IgMhi and IgMlo TS B cells to the TLR9 agonist CpG, which has
been proposed to driveMZB differentiation (Guerrier et al., 2012).
In culture, CpG increased surface expression of IgM on both IgMhi
and IgMlo B cells. However, IgMhi cells remained IgMhi compared
with the IgMlo cells (Fig. 5, C and D). Furthermore, culture with
CpG resulted in greater up-regulation of CD45RB on IgMhi TS and
IgMhi naive B cells than IgMlo TS and IgMlo naive B cells, consis-
tent with adoption of an MZP-like phenotype (Fig. 5 E).
A subpopulation of human cells with a TS B cell phenotype
are regulatory, and murine IL-10–producing B regulatory (B reg)
cells are T2 marginal zone progenitor cells, and the gut is im-
portant for their induction (Blair et al., 2010; Pillai et al., 2005;
Rosser et al., 2014). We therefore investigated the capacity of
IgMhi TS B cells to produce IL-10. Following 6-h stimulation with
PMA and ionomycin, IgMhi TS B cells produced significantly
more IL-10 than IgMlo cells (Fig. 5 F), inferring greater regula-
tory capacity of this subset.
MZB cell differentiation is defective in patients with
severe SLE
We have previously observed reduced frequencies of circulating
TS B cells expressing β7 integrin in a subset of SLE patients,
CD38, and IgM as clustering parameters. The tree displayed shows aggregated events from both concatenated GALT and PBMC samples. Automatic meta-
clustering of the FlowSOM nodes identified six metaclusters; the identity of each can be inferred by the relative expression of CD21, CD24, CD38, and IgM (see
also C). (C) Minimal spanning trees showing expression of CD21, CD24, CD38, and IgM on a concatenated (n = 7) PBMC sample. Clusters represent pheno-
typically similar cells, their size is proportional to the number of cells contained within them, and their color indicates the median expression of a given marker.
(D) Pie charts demonstrating the proportion of TS B cell subsets inferred from metaclusters in B confirm that GALT is enriched in IgMhi T2 cells. (E) Minimal
spanning trees demonstrating higher expression of CD69 and CD80 on GALT TS B cells. (F) Flow cytometry contour plots of concatenated (n = 3) liver
perfusate samples and concatenated HCD PBMC (n = 3). TS B cells were gated as CD27−IgD+CD10+ as illustrated in Fig. S1 D. A reduced proportion of
CD24++CD38++ T2 cells was observed in liver perfusates. (G) Flow cytometry plots of concatenated liver perfusate and PBMC samples demonstrating T2 cells
as gated in F and naive (CD27−IgD+CD10−) B cells as gated in Fig. S1 D. A reduced frequency of IgMhiCD24hi T2 and naive cells was observed in liver perfusate
samples compared with HCD PBMCs. (H) Flow cytometry dot plots with IgM mean fluorescence intensity (MFI) overlay of concatenated PBMC (n = 3) and liver
perfusate (n = 3) samples demonstrating reduced frequency of IgMhiCD24hi TS and naive B cells in liver perfusate samples. (I) Scatter plots of flow cytometry
data from individual samples gated as in G demonstrating reduced frequency of IgMhiCD24hi TS and naive B cells (CD27−IgD+CD10−) in liver perfusate samples
compared with PBMCs (median values).
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Figure 3. Transcriptomic analysis of IgMhi and IgMlo TS B cells demonstrates different upstream regulators of phenotype. (A) UMAP plot of IgMhi and
IgMlo TS B cells from five HCDs (see Fig. S2, A–D) clustered according to differentially expressed genes identified using the Seurat SCTransform workflow
(Hafmeister and Satija, 2019 Preprint). (B) Heatmap of selected genes from the top 60 differentially expressed genes in IgMhi and IgMlo TS B cells. (C) Scatter
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implying reduced potential for TS B cells to access GALT in these
cases. Data presented here implicate GALT as an important site
for MZB differentiation, and MZB depletion has been reported
in SLE (Rodŕıguez-Bayona et al., 2010; Zhu et al., 2018). Hence,
we sought to determine whether the stages of our proposedMZB
differentiation pathway were affected in SLE.
Flow cytometry was used to quantify B cell subsets in a co-
hort of 41 SLE patients and matched HCDs (Fig. S4, A and B).
Reduced MZB frequency was seen in patients with SLE com-
pared with HCDs (Fig. 6, A and B), and this was most marked in
patients with LN compared with patients with other manifes-
tations of SLE (other lupus subtypes [OLs]; Fig. 6 C). Reduced
MZB frequency was not a feature of other autoimmune diseases
studied (Figs. 6 C and S4 C), although it has been identified in
patients with Sjögren’s disease (Roberts et al., 2014). We found
that a relative reduction of MZB in patients with SLE was as-
sociated with a reduction of MZP (CD27−IgD+CD10−CD45RBhi
R123−; Fig. 6, D and E) and T3 CD45RBhi cells (CD27−IgD+
CD10−CD45RBhiR123+; Fig. 6, D and F). This was again most
consistently observed in the LN patient cohort. The proportion
of naive B cells (CD27−IgD+CD10−R123lo) was also diminished in
SLE (Fig. 6 G), but CD45RBloR123hi cells were more frequent
(Fig. 6 H). This population was further divided into T3 and aNAV
cells by their expression of CD24 and CD38 (Fig. 6 I).
CD45RBloR123hi cells were predominantly T3 cells (Fig. 6 J), al-
though both subsets were increased in patients with LN (Fig. 6, K
and L). Reduced frequency of MZB and precursor populations
was not secondary to demographics or immunosuppressants but
was more marked in more severe disease (Fig. S5, A–E). As
previously reported, CD27−IgD− DN cells were more abundant in
LN (Fig. 6 M). These were predominantly CD24loCD21lo and
therefore DN2, consistent with other studies (Jenks et al., 2018;
Fig. 6, N and O).
MZB depletion in SLE is therefore associated with reduced
frequency of MZP and T3 CD45RBhi cells. This consolidates the
concept of these cells as being in a developmental continuum in
health and suggests that altered transitional B cell maturation or
migration may result their depletion from the blood in SLE.
IgMhi β7 integrinhi T2 cells are reduced in frequency in LN
To identify early stages of aberrant marginal zone lineage de-
velopment in LN, we used mass cytometry to compare blood
B cell subsets from LN patients and HCDs in an undirected way
(Fig. S1, A–C). The automated clustering algorithm "cluster
identification, characterization, and regression" (CITRUS)
identified populations that differed significantly in abundance
between LN and HCDs. The three main clusters of nodes (Fig. 7
A) can be identified by their relative expression of B cell lineage
markers (Fig. 7, B and C). CD27−IgD+CD10− CD45RBhi (MZP) and
CD27+IgD+CD10− CD45RBhi (MZB) cells were significantly re-
duced in LN patients (Fig. 7 C [i and ii]). TS B cells were more
abundant (Fig. 7 C [iii]) while IgA class-switched cells were
reduced in patients with LN (Fig. 7 C [iv]).
TS B cell subpopulations in HCDs and LN were quantified by
FlowSOM (Fig. 7, D and E). Five metaclusters were identified
representing subdivisions of T1 and T2 populations (Fig. 7 D).
Inspection of minimal spanning trees demonstrated stark re-
duction of certain TS B cell subpopulations in LN (Fig. 7 E).
Quantification of events within metaclusters from all donors
revealed that T1 cells represented by metaclusters 1, 2, and 3
were more abundant in LN, while IgMhi T2 cells with high ex-
pression of β7 integrin represented by metacluster 4 were
markedly less abundant in LN (Fig. 7 F).
Reduced frequency of IgMhi T2 cells with high expression of
β7 integrin is therefore associated with MZB depletion in LN
patients. This supports the association between MZB and IgMhi
T2 cells in health and implicates reduced access of these cells to
GALT in the alteration of this developmental axis in patients
with severe lupus (Fig. S5 F).
Discussion
We have identified branches of human B cell lineage maturation
that are evident from the T2 stage. An IgMhi branch that ex-
presses higher levels of β7 integrin and lower levels of IL4R
compared with the IgMlo branch is gut homing. Confirmation of
differentiation through IgMhi stages of differentiation from
IgMhi T2, including IgMhiCD45RBhi T3 and naive B cell variants,
to MZBs is gained from pseudotime analysis coupled with the
observed concerted reduction of the stages in this sequence in
patients with severe SLE (Fig. S5 F).
The reduced frequencies of gut-homing IgMhi T2 cells in
severe SLE further consolidates the role of GALT in early B cell
fate decisions and supporting MZB development. Although it is
not clear whether reduced frequency of cells in this pathway in
blood reflects defects in differentiation, alternative homing
patterns, or cell death, the absence of the gut-homing MZB
maturational axis in blood in severe SLE affirms its existence in
health. It is also not clear whether alteration of our proposed
MZB differentiation pathway is a causative factor or a conse-
quence of inflammation. The inverse correlation of MZB counts
and disease activity may support the latter.
plot demonstrating genes differentially expressed in IgMhi and IgMlo TS B cells. (D) A PCA-based approach based on differentially expressed genes identified six
clusters among the IgMhi and IgMlo TS B cells that were demonstrated by UMAP. (E) Quantification of the frequency of IgMhi or IgMlo TS B cells within the
clusters demonstrated by UMAP in D reveals that IgMhi TS B cells dominate in clusters 0 and 2 and IgMlo TS B cells in clusters 1 and 3. (F) Dot plot dem-
onstrating expression of selected genes within clusters 0–3. (G) Flow cytometry dot plots demonstrating CD27−IgD+CD10+ cells as gated in Fig. S1 D. T2 cells
were gated as CD24++CD38++ and IgMhi and IgMlo subsets as 30% of cells with the highest and lowest expression of IgM respectively. (H) Scatter plots
demonstrating CD1c mean fluorescence intensity (MFI) in T1, IgMhi, and IgMlo T2 B cells gated in G (mean ± SD, paired t test). *, P < 0.05; ***; P < 0.001; ****,
P < 0.0001. (I) Histograms demonstrating CD1c MFI in B cell subsets as gated in Fig. S1 D. (J) Dot plot of flow cytometry data demonstrating CD27−IgD+CD10−
cells as gated in Fig. S1 D. Differential expression of CD45RB and R123 allowed the identification of CD45RBhi T3 (R123+) and MZP (R123−) cells. (K) A histogram
showing CD1c MFI on subsets as gated in J. (L) Dot plots demonstrating CD1c MFI on subsets gated in J (mean ± SD, paired t test). In J–L, RBHI refers to
CD45RBhi and RBLO refers to CD45RBlo. ***, P < 0.001; ****, P < 0.0001. FSC-A, forward scatter area.
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Figure 4. Lineage progression from IgMhi TS B cells through to MZBs. (A) A 3D UMAP plot of CD19+ cells from a HCD (10x HCD1, see Fig. S3 C) generated
from a PCA run on 2,000 differentially expressed genes. Clusters were merged and pseudocolored according to the B cell subsets they represent as described in
Fig. S3 (D–G). (B) CD27 and IgM ADT and CD1C gene signal overlay on the 3D UMAP plot displayed in A. (C) The 3D UMAP plot displayed in A viewed using
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We have previously observed that human T2 cells are re-
cruited into GALT, where they are activated by intestinal mi-
crobes (Vossenkämper et al., 2013). Here, we demonstrate that
specifically the IgMhi T2 subset of TS B cells is recruited into
GALT, where they have a phenotype of activated cells, including
expression of CD69 and CD80. The IgMhi T2 subset is also en-
riched in retinoic acid and LPS-inducible genes, consistent with
exposure to the microbiota. We show that the TLR9 agonist CpG
that up-regulates IgM and Notch 2 in human TS B cells
(Capolunghi et al., 2008; Guerrier et al., 2012) also up-regulates
CD45RB on IgMhi TS and IgMhi naive cells. PLD4, a lupus risk
allele and the most highly up-regulated gene in IgMhi compared
with IgMlo TS B cells, is up-regulated along the developmental
pathway to MZBs and limits responses to CpG (Gavin et al.,
2018). This suggests that PLD4 defects could contribute to
SLE pathogenesis by impacting an aspect of the development or
function of IgMhi TS B cells involving TLR9. Interestingly, PLD4
is also expressed in the splenic marginal zone in mice
(Yoshikawa et al., 2010), and PLD4 knockout mice develop
autoantibodies and immune complex–mediated renal damage
different UMAP axis coordinates. (D) CD27 and IgM ADT and CD1C gene signal overlay on the 3D UMAP projection in C. (E) A UMAP plot generated by in-
tegrating 3 HCD 10x datasets (see Fig. S3 C) and generated from a PCA run on 2,000 variably expressed genes. (F) Feature plots demonstrating overlay of ADT
signal on the UMAP plot from E enables identification of clusters representing TS and MZB cells. (G) A Slingshot developmental trajectory overlaid onto the
UMAP plot from E demonstrating developmental progression from clusters representing TS B cells to MZBs via IgMhi naive B cells. (H) A heatmap of selected
genes from the top 100 most differentially expressed genes along the Slingshot trajectory demonstrated in G. (I) Feature plots demonstrating overlay of gene
signal from the differentially expressed genes along the Slingshot trajectory identified in G.
Figure 5. IgMhi and IgMlo TS B cells differ functionally and in their potential to differentiate. (A) Histograms of flow cytometry data demonstrating cell
trace violet (CTV) dilution following 5 d of culture with CD40L + anti-IgM in IgMhi and IgMlo TS B cells from an HCD. (B) Scatter plots demonstrating increased
proliferation of IgMhi TS compared with IgMlo TS B cells when stimulated with CD40L + anti-IgM for 5 d (medians, Wilcoxon test). *, P < 0.05. (C) Flow
cytometry contour plots demonstrating that an IgMhi phenotype is maintained on IgMhi TS B cells after CpG stimulation for 5 d. (D) Scatter plots demonstrating
that an IgMhi phenotype is maintained on IgMhi TS B cells after CpG stimulation for 5 d (mean ± SD, paired t test). **, P < 0.01. (E) Flow cytometry contour plots
and scatter plots demonstrating greater up-regulation of CD45RB by IgMhi than IgMlo TS and naive (CD27−IgD+CD10−) B cell subsets at day 5 culture with CpG
(mean ± SD, paired t test). *, P < 0.05; **, P < 0.01. (F) Flow cytometry contour plots and scatter plots demonstrating higher frequency of IL10 expressing cells
among IgMhi TS B cells following 6-h stimulation with PMA/ionomycin (median, Wilcoxon test). *, P < 0.05.
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Figure 6. MZB cell differentiation is defective in patients with severe SLE. (A) Flow cytometry dot plots and scatter plots demonstrating reduced
frequency of CD27+IgD+ (MZB) cells in a patient with SLE compared with an HCD. (B) Scatter plots of flow cytometry data demonstrating reduced frequency of
MZB in patients with SLE compared with HCDs (medians, Mann–Whitney test). ****, P < 0.0001. (C) Scatter plots of flow cytometry data demonstrating
reduced MZB frequency in LN, other lupus subtypes (OL) but not in ulcerative colitis (UC), granulomatosis with polyangiitis (GPA), and PV (medians,
Mann–Whitney test). ***, P < 0.001; ****, P < 0.0001. (D) Flow cytometry dot plots of a HCD and an SLE patient demonstrating identification of T3 (R123hi)
and naive (R123lo) subsets with high and low expression of CD45RB. Stark reduced frequency of CD45RBhi T3 and naive (MZP) populations is evident in SLE.
(E) Scatter plot of flow cytometry data demonstrating reduced frequency of MZP (CD45RBhiR123lo) cells in LN patients (medians, Mann–Whitney test). *, P <
0.05; **, P < 0.01; ****, P < 0.0001. (F) Scatter plot of flow cytometry data demonstrating reduced frequency of CD45RBhi T3 (R123hi) cells in LN patients
(medians, Mann–Whitney test). ***, P < 0.001. (G) Scatter plot of flow cytometry data demonstrating reduced frequency of naive (CD45RBloR123lo) cells in LN
patients (mean ± SD, unpaired t test). *, P < 0.05; **, P < 0.01. (H) Scatter plot of flow cytometry data demonstrating enrichment of CD45RBloR123hi cells in LN
patients (mean ± SD, unpaired t test). *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. (I) Gating strategy to distinguish T3 (TS3) and aNAV cell subsets among
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similar to SLE with LN (Gavin et al., 2018). IgMhi TS B cells
also show a transcriptomic signature indicative of retinoic
acid regulation that is a feature of GALT microenvironment.
Together, these data suggest that innate signals and the gut
environment impact the origin, fate, and function of IgMhi
TS B cells.
Consistent with proposed developmental continuum from
the IgMhi T2 stage through to MZBs, GALT is involved in MZB
development, including a stage of receptor diversification in
GALT GCs. However, supporting a relatively short-term transit
coupled to differentiation, the frequencies of somatic mutations
in MZBs are lower than those of memory B cells or plasma cells
in the gut (Zhao et al., 2018). Together, these data suggest that
GALT transit and GC occupancy are important but transient
phases in IgMhi T2 to MZB lineage progression. Pseudotime
analysis also identified a population of B cells that appear to
develop fromMZBs and that are activated andmore mature. It is
possible that activation of MZBs might generate a novel popu-
lation of effector or memory cells.
MZB differentiation is associated with distinctive gene ex-
pression changes and acquisition of the transcription factor
ZEB2 (SIP1). ZEB2 has previously been identified as a component
of a network including miR200 and TGF-β1 that can regulate cell
fate decisions (Gregory et al., 2008; Guan et al., 2018). Activated
TGFβ-1 is produced abundantly in the gut. It is possible that in
addition to playing important roles in regulation of intestinal
immunity as a switch factor for IgA and induction of regulatory
T cells, it could also be involved in gut-associated MZB devel-
opment by interactions with ZEB2 (Borsutzky et al., 2004; Chen
et al., 2003).
Alteration of the MZB developmental pathway in the blood of
severe SLE patients was accompanied by expanded T3, aNAV,
and DN2 cell populations. Expansion of aNAV and DN2 pop-
ulations is a product of excessive TLR7 and IFN-γ signaling. We
were therefore interested in enrichment of IFN-γ–induced genes
in IgMlo TS B cells. Interestingly, the IFN-γ–regulated tran-
scription factor KLF2 was transcriptionally up-regulated in
IgMlo TS B cells. KLF2 drives follicular B cell maturation in mice
and its deletion results in an expansion of MZB cells. The role of
KLF2 in human B cell development is not known; however, loss-
of-function KLF2 mutations along with NOTCH2 mutations that
increase the stability of the notch intracellular domain are the
most commonly encountered mutations in human MZB cell
lymphoma (Campos-Mart́ın et al., 2017). This implicates KLF2 in
human B cell fate decisions, suggests a role for IFN-γ in B cell
development, and supports its proposed involvement of the
imbalance of B cell subsets in LN. The role of IFN-γ in defective
MZB maturation is also supported by reduction of this subset
in patients with severe COVID-19, which is associated with
elevated serum IFN-γ levels and extrafollicular B cell responses
(Laing et al., 2020; Woodruff et al., 2020).
LN represents a severe lupus subtype associated with the
worst clinical outcomes (Yap et al., 2012). B reg cell IL-10 re-
sponses associated with expression of CD80 and CD86 are de-
fective in SLE (Blair et al., 2010), permitting aberrant T effector
functions (Oleinika et al., 2019). In mice, B reg cells are
IgMhiCD21hiCD23hi T2 MZPs, and interaction with the gut mi-
crobiome is essential for their induction (Evans et al., 2007;
Rosser et al., 2014). We have identified that IgMhi TS B cells
express CD80 in GALT and represent the predominant IL-
10–producing TS B cell subset. Their reduction in LN may be
synonymous with the loss of B reg IL-10 responses and associ-
ated with the lack of T cell regulation in SLE. MZBs confer im-
munity to encapsulated bacteria such as pneumococcus, and
their reduction in LN may confer increased risk of such in-
fections in SLE (Danza and Ruiz-Irastorza, 2013). This also re-
inforces the importance of pneumococcal vaccination in this
patient cohort.
Undirected analysis of B cells in blood in LN compared with
HCDs identified reduction in IgA memory B cells in LN. IgA
deficiency can be observed in SLE, though the mechanism
driving this is not known (Cassidy et al., 2007; Odineal and
Gershwin, 2020). It is possible that lower expression of β7 in-
tegrin by B cells could contribute to IgA deficiency in SLE.
In summary, we identify an MZB maturation pathway that
becomes evident at the T2 stage of B cell development and that is
depleted in severe SLE. Traffic through GALT is a component of
this pathway that is potentially linked to the induction of human
IL-10–producing B reg cells (Rosser et al., 2014). Together, this
affirms the importance of tissue microenvironments in shaping
the B cell functional repertoire and maintaining health. Under-
standing the regulators of early B cell fate will be a key to re-
solving the disturbances in B cell function in severe SLE.
Materials and methods
Data and code availability
All raw and processed next-generation sequencing data have
been deposited with GEO under accession numbers GSE163602
and GSE163493. Code is available on github (https://github.com/
jspencer-lab/MZBFromT2).
Experimental subject details
All blood and tissue samples were obtained from adults with
research ethics committee (REC) approval and informed con-
sent. SLE patients were recruited using the following criteria: (1)
fulfilment of four or more revised American College of Rheu-
matology classification criteria, (2) ANA-positive, (3) biological
R123hiCD45RBlo cells on the basis of CD24 and CD38 expression. (J) Scatter plot demonstrating that R123hiCD45RBlo cells were mostly T3 cells as gated in I
(mean ± SD). (K) Scatter plot demonstrating increased frequency of T3 cells in OL and LN patients (mean ± SD, unpaired t test). *, P < 0.05; ****, P < 0.0001.
(L) Scatter plot demonstrating increased frequency of aNAV cells in OL and LN patients (mean ± SD, unpaired t test). **, P < 0.01. (M) Scatter plots showing the
proportion of CD27−IgD− B cells as gated in A demonstrate increased frequency of this population in LN (medians, Mann–Whitney test). *, P < 0.05. (N) Flow
cytometry dot plot demonstrating the identification of DN1 and DN2 cells based on expression of CD21 and CD24. (O) Scatter plot showing that DN2 cells as
gated in N were more abundant in LN and OL patients than in HCD (medians, Mann–Whitney test). ****, P < 0.0001.
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Figure 7. IgMhi β7 integrinhi T2 cells are reduced in frequency in LN. (A) CITRUS trees generated from CD19+ cells from HCDs (n = 8) and LN patients (n = 8)
and clustered according to the expression of CD5, CD9, CD10, CD24, CD27, CD38, CD45RB, IgD, IgM, and IgA (see also Fig. S1, A–C; and Fig. S4 A). CITRUS trees
represent nodes redundantly so that the most peripheral nodes contain cell populations that are progressively shared by more central nodes with the central
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(belimumab or rituximab) naive, and (4) immunosuppressive
regimen does not include azathioprine or cyclophosphamide
within 6 mo of sample collection due to the severe depletion of
naive B cells by thesemedications. All LN patients had diagnostic
confirmation by renal biopsy. Blood was obtained from SLE
patients and HCDs (REC reference 11/LO/1433: Immune regula-
tion in autoimmune rheumatic disease, London–City Road &
Hampstead Research Ethics Committee). Paired gut biopsies and
blood were obtained from individuals undergoing colonoscopies
in whom no mucosal abnormality was detected (REC reference
11/LO/1274: Immunology the intestine; features associated with
autoimmunity, London–Camberwell St Giles Research Ethics
Committee). Samples of cells draining the gut and spleen via the
hepatic portal vein were obtained from liver perfusion before
transplantation (REC reference 09/H0802/100: The role of
innate immune system in hepatic allograft outcome, Dulwich




Blood samples were diluted 1:1 in RPMI-1640 containing 10%
FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin (RPMI-P/S).
Diluted blood was then layered onto Ficoll and centrifuged for
25 min with brake and accelerator set to 0. The buffy coat layer
was then removed, and cells were washed in RPMI-P/S. PBMCs
isolated from patients undergoing colonoscopy was used fresh,
while PBMCs used for the analysis of HCDs and patients with SLE,
ulcerative colitis, granulomatosis with polyangiitis, and pemphi-
gus vulgaris (PV) were cryopreserved in FCS + 10% DMSO.
Mononuclear cells from gut were obtained by the removal of ep-
ithelial cells with 1 mM EDTA in HBSS containing 100 U/ml
penicillin and 100 µg/ml streptomycin for 30 min. Collagenase
digest was then used to generate a cell suspension using colla-
genase D (1 mg/ml) and DNase (10 U/ml) in RPMI-P/S for 1 h.
Mass cytometry
Three mass cytometry panels were used. The staining protocols
were as follows. Panel 1: Cryopreserved cells were washed and
rested in RPMI-P/S + 0.1 mg/ml DNase at 37 degrees for 45 min.
B cells were then negatively enriched using a Miltenyi B cell
isolation kit II. 4 × 106 cells were then viability stained with 1 ml
cisplatin 25 µM in 1× PBS. Cells were then washed in PBS con-
taining 0.5% BSA with 2 mM EDTA (cell staining medium [CS-
M]) and resuspended in 10 µl Fc receptor blocking solution and
left for 10 min on ice. IgG staining was then performed in 100 µl
staining volume for 30min on ice. Cells were thenwashed in CS-
M and resuspended in the pretitrated volume of antibody mas-
termix. The volume was then adjusted to 100 µl with CS-M, and
cells were stained for 30 min on ice. Metal-tagged antibodies
used are listed in Fig. S1 A. Cells were then washed twice in PBS
and fixed overnight in 16% paraformaldehyde. The following day
cells were washed in PBS and DNA was stained with 1 µM in-
tercalatin in 500 µl permeabilization buffer at room tempera-
ture for 20 min. Cells were then washed twice in PBS and twice
in Milli-Q water before being resuspended in Milli-Q water plus
EQ beads to a concentration of 0.5 × 106/ml and run on a Helios
Mass cytometer.
Panel 2: As for panel 1, except cells were stained fresh, were
not enriched, and 2 × 106 cells were viability stained with 1 ml
rhodium intercalator diluted in 1:500 in PBS for 20 min at room
temperature. Metal-tagged antibodies used are listed in Fig. S1 A.
Panel 3: As for panel 1, except cells were not enriched and IgG
staining was not performed. Metal-tagged antibodies used are
listed in Fig. S1 A.
Analysis of mass cytometry data
FCS files were normalized using Nolan laboratory software
(v0.3, available online at https://github.com/nolanlab/bead-
normalization/releases). A representative pre and post nor-
malization plot is shown in Fig. S1 B. Where files were concate-
nated, the Cytobank FCS File Concatenation Tool was used
(available online at https://support.cytobank.org/hc/en-us/
articles/206336147-FCS-file-concatenation-tool). Files were
then loaded onto the Cytobank (https://mrc.cytobank.org/) and
gated to identify live CD19+ B cells (Fig. S1 C).
For the analysis of HCD PBMCs in Fig. 1, viSNE was run on
equal numbers of CD19+ events (n = 35,000) from each HCD (n =
10). SPADE was then run on the viSNE coordinates, and B cell
subsets were identified by placing nodes into bubbles. The TS
bubble was identified as CD27−IgD+CD24+++/++CD38+++/++. Events
within the TS bubble were exported, a further viSNE was run
using equal events (n = 3,535) and all panel markers except
CD45, CD3, CD14, and class-switched isotypes IgA and IgG,
which are not expressed by TS B cells. CD45 was excluded due to
homogenous expression and lack of contribution to clustering.
SPADE was then run on the viSNE coordinates, and TS B cell
populations were defined as demonstrated in Fig. 1 B.
For the analysis of PBMCs and GALT-derived B cells in Fig. 2,
equal numbers of CD19+ events (n = 118,934) from concatenated
PBMC (n = 7) and GALT (n = 7) samples were used to run a viSNE
using all markers except for CD45, CD3, and CD14. SPADE was
then run on the viSNE coordinates and TS B cells identified as
CD27−IgD+CD10+ nodes. Events within the TS bubble were then
node containing all events. Red nodes indicate significantly different population abundances between HCDs and LN patients. A gray background is auto-
matically assigned to aggregates of significant nodes. Arrows and roman numerals indicate nodes further analyzed in C. (B) CITRUS trees demonstrating the
median expression of the clustering panel markers in the nodes. (C) Histograms demonstrating the abundance and expression of panel markers in selected
nodes. The identity of these nodes can be inferred as (i) MZP, (ii) MZB, (iii) TS B cells, and (iv) class-switched IgA memory. (D)Minimal spanning tree generated
by FlowSOM from events exported from CITRUS node (iii) representing TS B cells identified in A and C. This generated five metaclusters; the identification of
each could be inferred by median expression of panel markers in each metacluster. (E) Minimal spanning trees generated by FlowSOM plots demonstrating
CD38 expression in a representative HCD and LN patient. Prominent skewing of TS B cell subpopulations is evident in LN. (F) Relative abundances of
metaclusters as a percentage of TS B cells indicate reduced frequency of events within metacluster 4 corresponding to IgMhi β7hi TS B cells in LN and increased
frequency of events in metaclusters 1, 2, and 3 corresponding to T1 cells (medians, Mann–Whitney test). **, P < 0.01; ***, P < 0.001.
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exported, and equal numbers of events (n = 4,520) were clus-
tered using FlowSOM. CD10, CD24, CD38, and IgM as clustering
channels to allow the undirected visualization of markers on TS
B cell populations.
For the analysis of PBMCs from HCDs and SLE samples in
Fig. 7, CITRUS was run using equal numbers of CD19+ events (n =
20,000) from HCDs (n = 8) and SLE patients (n = 8) and the fol-
lowing clustering channels: CD5, CD9, CD10, CD24, CD27, CD38,
CD45RB, IgD, IgM, and IgA. Due to event sharing among CITRUS
nodes, node 321,672 identified in Fig. 7, A and C (iii), contains all
CD27−IgD+CD24+++/++CD38+++/++ events andwas therefore used for
analysis of TS B cells. All events from this nodewere exported, and
FlowSOMwas run using equal event sampling (n = 657) and using
all marker channels except CD45, CD3, CD14, and IgA.
Flow cytometry and cell sorting
Cryopreserved cells used for flow cytometry were thawed and
washed in RPMI-P/S and then rested at 37°C in RPMI-P/S +
0.1 mg/ml DNase for 45 min. Viability staining with Zombie
aqua dye was performed using 100 µl 1:200 dilution in 1× PBS, or
with DAPI 0.1 mg/ml diluted 1:1,000 and added before sample
acquisition on the flow cytometer. Cells were stained on ice for
15 min with pretitrated concentrations of antibodies. Staining
with R123 was performed for 10 min at a concentration of 6 µM,
and cells were washed and chased for 3 h in RPMI-P/S. All
samples were analyzed by a BD LSRFortessa (BD Biosciences).
Anti-Mouse/Rat beads (BD Biosciences) were used for fluores-
cent compensation, and gates were set using appropriate isotype
controls. Cell sorting was performed using a BD FACSAria (BD
Biosciences), and live single CD19+ B cells were gated as follows:
IgMhi TS: CD27−IgD+CD10+IgMhi, IgMlo TS: CD27−IgD+CD10+IgMlo;
IgMhi naive: CD27−IgD+CD10−IgMhi; IgMlo naive: CD27−IgD+
CD10−IgMlo; where IgMhi and IgMlo gates captured 30% of the
highest and lowest IgM-expressing cells, respectively.
Cytokine detection
Fresh PBMCs were isolated from HCDs and incubated for 6 h at
37°C with 50 ng/ml PMA and 250 ng/ml ionomycin with Gol-
giPlug at a dilution of 1:1,000. Cells were then surface stained as
above followed by fixation with Cytofast buffer (BioLegend).
Cells were then washed twice and stained with resuspended
conjugated antibodies in permeabilization/wash buffer (Bio-
Legend) for 20 min at room temperature.
Cell culture and stimulation analysis
Sorted IgMhi and IgMlo TS and naive (CD27−IgD+CD10−) B cell
subsets were plated onto a 96-well plate seeded with 2 × 104 cells
per well. Wells containing CD40L-expressing HEK cells were
also seeded with 2 × 104 irradiated HEK cells per well. Cells were
then stimulated with CpG-ODN 2.5 µg/ml or anti-IgM 10 µg/ml.
Proliferation assays were performed on cells stained with Cell-
Trace violet as per the manufacturer’s guidelines. Cells were
then stained and analyzed by flow cytometry as above.
Single-cell RNA-sequencing library preparation
Sorted cell populations were loaded onto a 10x Genomics
ChromiumController, and 59 gene expression, VDJ, and ADT (for
samples in Fig. 4) were prepared according to the manu-
facturer’s guidelines. Samples used in Fig. 3 were sequenced
using an Illumina NextSeq 500 platform. Samples used in Fig. 4
were sequenced using an Illumina HiSeq 2500 High Output
platform. The 10x Genomics Cell Ranger workflow was then
used for transcript alignment and the generation of sparse ma-
trices for downstream analysis.
CITE-seq antibody staining
Cryopreserved samples were thawed and sorted using the gating
strategy in Fig. S3 A. Cells were then washed and stained in a
CITE-seq antibody cocktail at a concentration of 8 µg/ml for
30 min on ice (Fig. S3 B). Cells were then washed three times
before loading onto the 10x Chromium controller.
Single-cell sequencing analysis
The Seurat R package (vs 3.1.1) was used to filter data to remove
cells with low numbers of RNA transcripts, doublets, and cells
with high levels of mitochondrial transcripts indicative of cell
death. Immunoglobulin variable genes were then removed from
the dataset as well as cells with low expression of B cell genes
CD79A, CD79B, CD19, or MS4A1. Data from IgMhi and IgMlo TS
B cells were merged, and the data were transformed in accor-
dance with the SCTransform workflow before UMAP-based
reduction of dimensionality and PCA-based clustering to iden-
tify populations (Hafmeister and Satija, 2019 Preprint). Heat-
maps were then created using select genes from the top 60
differentially expressed genes in each sample and dot plots and
violin plots on selected genes. Data from sorted CD19+ cells
from HCDs used for Fig. 4 and Fig. S3 were initially analyzed
individually followed by an integrated analysis. Individual
analysis was performed using the quality control steps as well
as the removal of IGHV genes and non B cells as described
above. Data were then normalized and scaled and UMAP run on
a PCA generated using 2,000 variable genes. Overlay of ADT
and gene signal, violin plots, and median expression of markers
by UMAP clusters was used to identify which B cell subsets
they corresponded to. For the integrated data analysis, data
from three HCDs were filtered using the quality control steps
as well as the removal of IGHV genes and non–B cells as de-
scribed above. Data were then normalized using the SCTrans-
form wrapper in Seurat followed by integration using The
Satija Laboratory Integration and Label Transfer protocol
(Butler et al., 2018), with 3,000 integration features. The 2,000
most variable genes were then used to perform PCA, and a 3D
UMAP was obtained from this. Clusters were obtained using
the FindNeighbors and FindClusters functions within Seurat
using default parameters. The UMAP coordinates and cluster
allocations were then used to run Slingshot (Street et al., 2018).
Randomized downsampling of 50% was required to improve
the performance of trajectory inference in Slingshot. ADT
overlay of the UMAP plot was used to identify the cluster
composed of CD27−IgD+CD38hi cells that best represented TS
B cells, and this was chosen as the starting point from which
Slingshot would build trajectories. A heatmap was then created
using genes of interest among the top 100 differentially ex-
pressed genes on the trajectory.
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Quantitative RT-PCR
Quantitative RT-PCR was performed using Taqman Gene Ex-
pression Assays (FAM; Thermo Fisher Scientific) were used to
quantify CCR7 and ITGB7 expression in cDNA from sorted IgMhi
and IgMlo TS B cell subsets. Reactions were performed in du-
plicate and multiplexed with Eukaryotic 18S rRNA Endogenous
Control (VIC). Samples were run on a QuantStudio 5 Real Time
PCR System (Thermo Fisher Scientific). ΔCT was calculated
using Thermo Fisher Connect software (available online at
(https://apps.thermofisher.com/apps/spa/#/dataconnect).
Quantification and statistical analysis
Flow cytometry and mass cytometry data
Flow cytometry data were visualized and gated using FlowJo v
10.6.1. Mass cytometry data were analyzed using Cytobank
software.
Statistical analysis
GraphPad Prism version 7.0 was used for statistical analysis.
Paired t tests or Wilcoxon tests were used to compare paired
samples while unpaired t tests or Mann–Whitney tests were
used for unpaired samples. Adjusted P values are represented as
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. All error
bars show the mean ± SD.
Online supplemental material
Fig. S1 illustrates antibody panels, normalization and gating
strategy for mass cytometry, flow cytometry gating relating to
Figs. 2 and 3, and a heatmap relating to Fig. 2 B. Fig. S2 illustrates
the sorting strategy, 10x Genomics workflow, and validation of
data in Fig. 3. Fig. S3 illustrates the sorting strategy and 10x
Genomics workflow, identification of B cell subsets represented
by UMAP clusters in 10x HCD 1 in Fig. 4, and 3D UMAP plots
illustrating B cell subsets in 10x HCD 2 and 3. Fig. S4 provides
demographic data for patients and healthy controls. Fig. S5
shows the relationship between MZB counts and SLE clinical
parameters and also a model of B cell development that includes
alterations observed in SLE. Video 1 shows rotation of the 3D
UMAP plot demonstrating B cell subsets from 10x HCD1 as de-
picted in Fig. 4 A. Video 2 shows rotation of the 3D UMAP plot
demonstrating B cell subsets from 10x HCD2 as demonstrated in
Fig. S3 H. Video 3 shows rotation of the 3D UMAP plot demon-
strating B cell subsets from 10x HCD3 as demonstrated in Fig. S3
I. Video 4 shows rotation of 3D UMAP plot as depicted in Fig. 4 G
with overlay of IgM ADT signal demonstrating that the Slingshot
trajectory passes through IgMhi naive B cells.
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Gavin, A.L., D. Huang, C. Huber, A. Mårtensson, V. Tardif, P.D. Skog, T.R.
Blane, T.C. Thinnes, K. Osborn, H.S. Chong, et al. 2018. PLD3 and PLD4
are single-stranded acid exonucleases that regulate endosomal nucleic-
acid sensing. Nat. Immunol. 19:942–953. https://doi.org/10.1038/s41590
-018-0179-y
Gregory, P.A., A.G. Bert, E.L. Paterson, S.C. Barry, A. Tsykin, G. Farshid, M.A.
Vadas, Y. Khew-Goodall, and G.J. Goodall. 2008. The miR-200 family and
miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1
and SIP1. Nat. Cell Biol. 10:593–601. https://doi.org/10.1038/ncb1722
Guan, T., C.X. Dominguez, R.A. Amezquita, B.J. Laidlaw, J. Cheng, J. Henao-
Mejia, A.Williams, R.A. Flavell, J. Lu, and S.M. Kaech. 2018. ZEB1, ZEB2,
and the miR-200 family form a counterregulatory network to regulate
CD8+ T cell fates. J. Exp. Med. 215:1153–1168. https://doi.org/10.1084/jem
.20171352
Guerrier, T., P. Youinou, J.O. Pers, and C. Jamin. 2012. TLR9 drives the de-
velopment of transitional B cells towards the marginal zone pathway
and promotes autoimmunity. J. Autoimmun. 39:173–179. https://doi.org/
10.1016/j.jaut.2012.05.012
Hafmeister, C., and R. Satija. 2019. Normalization and variance stabilization of
single-cell RNA-seq data using regularized negative binomial regression.
bioRxiv. https://doi.org/10.1101/576827 (preprint posted March 18, 2019)
Hammad, H., M. Vanderkerken, P. Pouliot, K. Deswarte, W. Toussaint, K.
Vergote, L. Vandersarren, S. Janssens, I. Ramou, S.N. Savvides, et al.
2017. Transitional B cells commit to marginal zone B cell fate by Taok3-
mediated surface expression of ADAM10. Nat. Immunol. 18:313–320.
https://doi.org/10.1038/ni.3657
Hart, G.T., X. Wang, K.A. Hogquist, and S.C. Jameson. 2011. Krüppel-like
factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and
trafficking molecule expression. Proc. Natl. Acad. Sci. USA. 108:716–721.
https://doi.org/10.1073/pnas.1013168108
Jenks, S.A., K.S. Cashman, E. Zumaquero, U.M. Marigorta, A.V. Patel, X.
Wang, D. Tomar, M.C. Woodruff, Z. Simon, R. Bugrovsky, et al. 2018.
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7
Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.
Immunity. 49:725–739.e6. https://doi.org/10.1016/j.immuni.2018.08.015
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Figure S1. Mass cytometry antibody panels, normalization, and gating strategy. (A)Mass cytometry panel used for analysis in Fig. 1 A, Fig. 2 B, and Fig. 7 C.
(B) Pre- and postnormalization plots of mass cytometry data used for Fig. 1, which is representative of the mass cytometry data used in Figs. 2 and 7.
(C) Gating strategy of mass cytometry data used to identify live CD19+ B cells. Cleanup residual, center, offset, and length gates were not used for the data
displayed in Fig. 2. (D) Flow cytometry plots demonstrating identification of T1 and T2 cells as CD27−IgD+CD10+ cells that are CD24+++/CD38+++ and CD24++/
CD38++ respectively, T3 cells as CD27−IgD+CD10−R123hi, and naive (N) B cells as CD27−IgD+CD10−R123lo. CSM, class-switched memory. (E) SPADE trees
demonstrating expression of IgM and CD45RB in the concatenated GALT sample (see also Fig. 2 A). (F) Heatmap demonstrating the median expression of panel
markers from metaclusters 3 and 4 displayed in Fig. 2 B. SSC-A, side scatter area; SSC-W, side scatter width.
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Figure S2. Sort strategy, 10x Genomics workflow and validation. (A) FACS sort strategy to identify IgMhi and IgMlo TS B cell subsets. (B) Purity plots of
sorted IgMhi and IgMlo TS B cell subsets. (C) 10x Genomics experimental workflow detailing pooling of HCD samples. (D) Summary table of cell numbers
captured by the 10x controller and sequencing depth of IgMhi and IgMlo TS B cell subsets. (E) Violin plot demonstrating expression of the IL4R gene in IgMlo TS
B cells. (F) Scatter plots of flow cytometry data demonstrating higher frequency of IL4R on IgMlo compared with IgMhi TS (CD27−IgD+CD10+) and naive
(CD27−IgD+CD10−) cells (mean ± SD, paired t test). *, P < 0.05. (G) Violin plot demonstrating expression of the SELL (CD62L) gene in IgMlo TS B cells. (H) qPCR
confirms higher levels of the SELL gene transcript in IgMhi TS B cells expressed as ΔCT values relative to an 18S endogenous control (paired t test). *, P < 0.05.
(I) Ingenuity pathway analysis (IPA) upstream regulator plot demonstrating enrichment of LPS induced genes in IgMhi TS B cells. (J) IPA upstream regulator plot
demonstrating enrichment of retinoic acid induced genes in IgMhi TS B cells. (K) IPA upstream regulator plot demonstrating enrichment of IFN-γ induced genes
in IgMlo TS B cells. (L) Bar graphs demonstrating a lower frequency of VH1 and higher frequency of VH3 immunoglobulin variable heavy chain gene usage in
IgMhi TS B cells than TS IgMlo cells (Chi squared test with Bonferroni correction). *, P < 0.05; ***, P < 0.001. (M) Scatter plot of flow cytometry data from HCD
demonstrating that T3 and naive CD45RBhi subsets as gated in Fig. 3 J share high IgM expression (mean fluorescence intensity [MFI] mean ± SD, paired t test).
****, P < 0.0001. (N) T3 and naive CD45RBhi subsets share similar high surface expression of CD24 (MFI mean ± SD, paired t test). ****, P < 0.0001. FSC-H,
forward scatter height; SSC-H, side scatter height.
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Figure S3. Sort strategy, 10x Genomics workflow and identification of B cell subsets represented by UMAP clusters in 10x HCD1. (A) Gating strategy
to sort live CD19+ cells. (B) TotalSeq antibodies and clones used for surface labeling of CD19+ B cells. (C) Demographic details of HCDs, cells captured, and
sequencing depth. (D) UMAP plot demonstrating clusters generated from a PCA run on 2,000 differentially expressed genes from 10x HCD1. (E) Feature plots
demonstrating lineage defining ADT (CITE-seq antibody) and transcript signal overlay on the UMAP plot. (F) Table of median IgM (IGM) expression within
clusters representing naive cells (CD27−IgD+CD38int). The top 30% of clusters were designated as IgMhi and designated H in the column labeled ID. The
remainder of clusters that were not IgMhi are designated N. (G)Merged and pseudocolored clusters representing B cell subsets defined by ADT and gene signal
of lineage defining targets. CSM, class-switched memory. (H) A 3D UMAP plot demonstrating merged and pseudocolored clusters representing B cell subsets
from 10x HCD2. (I) A 3D UMAP plot demonstrating merged and pseudocolored clusters representing B cell subsets from 10x HCD3. FSC-A, forward scatter
area; SSC-A, side scatter area.
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Figure S4. Patient and HCD demographic tables. (A) Table of SLE patient demographic data used for Figs. 6 and 7. AC, African Caribbean; Arth., in-
flammatory arthritis; C, Caucasian; Cut., cutaneous lupus; dsDNA, double-stranded DNA; Eth., ethnicity; HCQ, hydroxychloroquine; MMF, mycophenolate
mofetil; Neph., LN; PRED, prednisolone; SEA, Southeast Asian; ANA, antinuclear antibodies; RNP, ribonucleoprotein; La, Ro, and Sm are examples of ribonuclear
protein autoantigens. (B) Table of HCD demographic data used in Fig. 6. IA, Indian Asian. (C) Table of demographic data of patients with other autoimmune
diseases. AZA, azathioprine; GPA, granulomatosis with polyangiitis; MES, mesalazine; MTX, methotrexate; UC, ulcerative colitis.
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Figure S5. The relationship between MZB counts and SLE clinical parameters and a proposed model of defective B cell development in SLE.
(A) Scatter plots of flow cytometry data demonstrating no difference in MZB frequency in African Caribbean (-AC) and Caucasian (-C) HCD and SLE patients
(medians, Mann–Whitney test). (B) Correlation of MZB and SLE disease activity index (SLEDAI) score in Caucasian SLE patients (Spearman’s rank coefficient).
(C) Bar graphs demonstrating the immunosuppressive burden of SLE patients with low MZB counts (<3.13% CD19+ cells) versus high MZB counts (>3.13%
CD19+ cells), where 3.13% represents the median MZB value in all SLE patients. MMF, mycophenolate mofetil; HCQ, hydroxychloroquine; PRED, prednisolone.
(D) Scatter plots of flow cytometry data demonstrate that PV patients taking mycophenolate mofetil and/or prednisolone did not have reduced MZB when
compared with SLE patients on the same immunosuppressive medication (mean ± SD, unpaired t test). (E) Scatter plots of flow cytometry data demonstrate
there was no difference in MZB counts in nonrenal SLE (OL) patients taking or not taking hydroxychloroquine (HCQ) therapy (medians, Mann–Whitney test).
(F) Proposed model of MZB differentiation and alterations seen in severe SLE.
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Video 1. Rotation of the 3D UMAP plot demonstrating B cell subsets from 10x HCD1 as depicted in Fig. 4 A. Playback speed, 10 frames per second (see
also Fig. S3, D–G).
Video 2. Rotation of the 3D UMAP plot demonstrating B cell subsets from 10x HCD2 as demonstrated in Fig. S3 H. Playback speed, 10 frames per
second.
Video 3. Rotation of the 3D UMAP plot demonstrating B cell subsets from 10x HCD3 as demonstrated in Fig. S3 I. Playback speed, 10 frames per
second.
Video 4. Rotation of 3D UMAP plot as depicted in Fig. 4 G with overlay of IgM ADT signal demonstrating that the Slingshot trajectory passes
through IgMhi naive B cells. Playback speed, 10 frames per second.
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